Merck hope to develop biologic drug conjugates using Ambrx’s “site-specific protein medicinal chemistry technology”
Merck is paying an upfront fee of $15 million and is eligible to receive milestones totalling up to $288 million. Ambrx will also receive royalties.
Richard Murray, head of biologics and vaccines research at Merck said that this collaboration will allow us to combine Ambrx’s expertise in site-specific protein conjugation chemistry with Merck’s expanding antibody capabilities and extensive small molecule resources.
Follow us on Twitter @CKScienceJobs to receive more industry news and CK jobs of the week updates